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IndoleamineIndolic derivatives can affect ﬁbril growth of amyloid forming proteins. The neurotransmitter serotonin (5-
HT) is of particular interest, as it is an endogenous molecule with a possible link to neuropsychiatric
symptoms of Parkinson disease. A key pathomolecular mechanism of Parkinson disease is the misfolding and
aggregation of the intrinsically unstructured protein α-synuclein. We performed a biophysical study to
investigate an inﬂuence between these two molecules. In an isolated in vitro system, 5-HT interfered with α-
synuclein amyloid ﬁber maturation, resulting in the formation of partially structured, SDS-resistant
intermediate aggregates. The C-terminal region of α-synuclein was essential for this interaction, which
was drivenmainly by electrostatic forces. 5-HT did not bind directly tomonomericα-synucleinmolecules and
we propose a model where 5-HT interacts with early intermediates of α-synuclein amyloidogenesis, which
disfavors their further conversion into amyloid ﬁbrils.-HT, 5,7 dihydroxytryptamine;
T; TEM, transmission electron
n, non-Aβ component region
+43 316 3809840.
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The 14 kDa polypeptide α-synuclein (AS) is a signature protein of
Parkinson disease (PD), a neuromotor disorder which is characterized
by the death of dopaminergic neurons within the substantia nigra of
the brain [1]. AS is the major constituent of proteinaceous amyloido-
genic inclusions known as Lewy bodies, which are the histological
hallmarks of PD [2–4].
AS is intrinsically unstructured [5]. It is composed of an N-terminal
amphipathic region, a central aggregation prone NAC (non-Aβ-
component) hydrophobic region, and an acidic C-terminal region.
The high degree of conformational freedom within these regions
inﬂuences folding and aggregation of AS, two processes that closely
couple this molecule to neurotoxicity [6]. While AS adopts β-sheet
conformation in amyloid ﬁbrils [7], soluble folding intermediates
assemble into aggregates of different size and shape [8–14]. A growing
number of studies suggest that the neurotoxic agents of the disease
are soluble, intermediately folded AS-oligomers rather than amyloid
ﬁbrils [8–13,15]. The generation of soluble aggregates depends on anumber of factors such as natural mutations of the AS gene, molecular
chaperones, and the interaction with several chemically and func-
tionally unrelated small molecule ligands [6]. The non-homogeneous
nature of these folding intermediates is reﬂected in their variable
cytotoxic activity. Some conditions force the accumulation of non-
toxic aggregates [16,17], while others promote pronouncedly neuro-
toxic species [9,12,13].
Several studies suggest that, in PD, the crucial interplay between
AS and the neurotransmitter dopamine, dopamine oxidation inter-
mediates, and other catechols promotes the generation of distinct
aggregates and they may represent toxic species triggering dopami-
nergic cell death [18–25] and ultimately neuromotoric impairment.
Intriguingly, it was suggested that an indolic oxidation intermediate
of dopamine, namely 5,6-dihydroxylindole, interferes with the
assembly of AS rather than dopamine itself [26,27]. Indole-scaffold
derivatives affecting the assembly of different amyloid forming
proteins have also been identiﬁed in various small molecule screening
assays [28–32]. The indoleamine neurotransmitter serotonin (5-HT)
[29] captured our particular attention, since in neurodegenerative
diseases, altered levels of 5-HT are linked to neuropsychiatric
impairments such as sleep abnormalities, depression, and anxiety
[33–36]. In PD, altered 5-HT metabolism may be linked to the non-
motor symptoms of the disease [35]. This led us to investigate
whether 5-HT affects the folding and aggregation of AS, in analogous
manner to what has been established for dopamine and its
derivatives.
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Fig. 1. (A) ThioT amyloid growth kinetics of 100 μM AS in the absence (■) and in the
presence of 1 mM 5-HT (○); 100 μM AS seeded with approximately 100 nM of 5-HT
induced aggregates (□). (B) ThioT ﬂuorescence of 100 μM AS after 5 days in
dependence of increasing concentrations of 5-HT.
554 S.F. Falsone et al. / Biochimica et Biophysica Acta 1814 (2011) 553–561We found that, in an in vitro isolated system, 5-HT binds to and
stabilizes AS aggregates of a heterogeneous composition, which
consequently accumulate instead of growing into mature ﬁbrils. This
effect is particularly sensitive to charge perturbations, and we identify
a prevalent role for electrostatic interaction with the C-terminal
region of AS.
2. Materials and methods
Unless speciﬁed otherwise, all reagents were from Sigma (St.
Louis, MO).
2.1. Protein expression and puriﬁcation
The pRSETB vectors containing the human AS gene and the ASΔ96
gene were transformed into BL21 (DE3) Star cells (Invitrogen, Carlsbad,
CA). ASwasexpressed in LBmediumcontaining100 μg/ml ampicillin.
15
N-
labeled AS (
15
N-AS) was expressed in minimal medium (6.8 g/l Na2HPO4,
3 g/l KH2PO4, 0.5 g/l NaCl, 1.5 g/l (
15
NH4)2SO4, 2 g/l glucose, 1 μg/l biotin,
1 μg/l thiamin, 100 μg/ml ampicillin, and 1 ml 1000× microsalts).
Cultures were grown at 37 °C to an OD600 of 0.7. The protein
expression was induced by the addition of 1 mM IPTG. After 4 h, cells
were harvested by centrifugation at 6000g for 15 min at 4 °C. The cells
were resuspended in 20 mM Tris–HCl, 50 mM NaCl, pH 7.4 (buffer A),
supplemented with a Complete® protease inhibitor mix (Roche, Basel,
Switzerland) anddisruptedon iceby soniﬁcation.After centrifugation, an
acid precipitation step was performed by lowering the pH to 4 and
stirring for 20 min at 4 °C. The precipitatewas removedby centrifugation
at 20,000g for 1 h and the supernatant was loaded onto a Source Q
columnwhichwaspreviously equilibratedwithbuffer A. The elutionwas
carried out using a gradient from 50 mM to 600 mM NaCl. The fractions
containing protein were pooled, loaded on a Superdex 75 gel ﬁltration
column (GE Healthcare, Uppsala, Sweden), and eluted with H2O. The
puriﬁed protein was aliquoted, lyophilized, and stored at−80 °C.
ASΔ96 was expressed in LB-medium containing 100 μg/ml
ampicillin. The puriﬁcation was similar to that of AS, except that a
heat precipitation step was performed instead of acid precipitation
(80 °C, 10 min under stirring). Also, an SP-sepharose column (GE
Healthcare, Uppsala, Sweden) was used instead of a Source Q column.
2.2. Thioﬂavin T (ThioT) and turbidity measurements
Unless otherwise described, a 100 μM AS or ASΔ96 solution in
20 mM Tris–HCl, 150 mM NaCl, 3 mM NaN3, pH 7.4, was agitated in a
thermomixer (Eppendorf, Hamburg, Germany) at 37 °C and
1200 rpm. Ten microliter aliquots were taken at the indicated time
points and diluted into a ﬁve micromolar ThioT solution prepared in
the same buffer. Spectra of the samples were recorded on a Cary
Eclipse ﬂuorescence spectrometer (Varian, Palo Alto, CA) at 25 °C and
482 nm upon excitation at 442 nm. The slit widths were set to 10 nm
and 20 nm for excitation and emission, respectively.
The turbidity of the same samples was measured on a Cary Eclipse
ﬂuorescence spectrometer (Varian, Palo Alto, CA) at 25 °C with
excitation and emission wavelengths set at 360 nm using a slit width
of 5 nm for both excitation and emission.
The values are averages including S.E. of three independent
determinations.
2.3. Circular dichroism
Far-UV-circular dichroismmeasurements were performed at 25 °C
on a J-715 spectropolarimeter (Jasco, Tokyo, Japan) with a response
time of 2 s and with a data point resolution of 0.1 nm using a 0.1 cm
quartz cuvette. The spectra were recorded by diluting the samples in
20 mM NaPi, pH 7.4. Three scans were averaged to obtain smooth
spectra.To eliminate the signal contribution of residual monomeric AS
from the aggregate spectrum, the ratio of monomer to oligomer AS
was determined by 1H-NMR under the assumption that no other
species is present in solution. This was then subtracted from the
original spectrum.
Mean residue ellipticity calculations and secondary structure
deconvolution analysis were performed on the DICHROWEB platform
[37] by applying the SELCON3 algorithm [38].
2.4. Dynamic light scattering (DLS)
Stokes radii were determined using a DynaPro instrument (Protein
Solutions, Lakewood, NJ) in a 1.5 mm pathlength 12 μl quartz cuvette
at 25 °C. Samples were centrifuged before measuring. The values are
averages including S.E. of three independent determinations.
2.5. NMR spectroscopy
All NMR spectra were acquired at 300 K on a Bruker Avance DRX
500 MHz NMR spectrometer equipped with a 5 mm TXI triple-
resonance probe and z-axis gradients. One-dimensional
1
H-NMR
spectra were recorded on a solution containing 50 μM 5-HT and
100 μM AS in 20 mM Tris–d11, 150 mM NaCl, 3 mM NaN3, pH 7.4, and
containing 10% (vol./vol.) of D2O. The solution was shaken for 7 days
at 1200 rpm at 37 °C. Every 24 h, a one-dimensional
1
H NMR spectrum
with Watergate solvent suppression was acquired with 1024 scans.
Two-dimensional
1
H-
15
N-HSQC spectra were recorded on a 100 μM AS
Fig. 2. (A) Turbidity of 100 μMAS in the absence (■) and presence of 1 mM5-HT (○). (B) DLS of 100 μMAS in the absence (■) and presence of 1 mM 5-HT (○). Themean Stokes radii
of the predominating AS species of each sample were plotted against the time. (C) Denaturing SDS–PAGE aggregation proﬁle of 100 μMAS agitating at 37 °C shows that SDS-resistant
species appear over time in the presence of 1 mM 5-HT. (D) Denaturing SDS–PAGE aggregation proﬁle of 100 μM AS agitating at 37 °C in the presence of 10 mM sodium thiosulfate.
(E) The amyloid inhibiting effect of 5-HT measured at t=100 h in the absence and in the presence of 10 mM of the reducing agent sodium thiosulfate.
555S.F. Falsone et al. / Biochimica et Biophysica Acta 1814 (2011) 553–561solution in 50 mM NaPi, 50 mM NaCl, 3 mM NaN3, pH 6.5, in the
absence and in the presence of 1 mM 5-HT. Ten percent D2O were
added for ﬁeld-frequency locking. Data were processed using
NMRPipe [39].
2.6. Transmission electron spectroscopy
A protein suspension was placed onto carbon-coated grids, blot
dried, and rinsed in distilled water for 1 min. Negative staining was
performed by applying 1% uranyl acetate for 1 min and blotting theliquid with ﬁlter paper. Afterwards, the samples were air-dried and
viewed with a Zeiss EM 901 transmission electron microscope.
2.7. Ultraﬁltration assays
A 100 μM AS solution in 20 mM Tris–HCl, 150 mM NaCl, pH 7.4,
was agitated in a thermomixer (Eppendorf, Hamburg, Germany) at
37 °C and 1200 rpm in the presence of equimolar amounts of 5-HT.
Fifty microliters of the solution were then removed at given times and
spun at 13,000g for 5 min through an Amicon Ultra-0.5 centrifugal
Fig. 3. TEM images of 100 μMAS in the absence (A) and in the presence (B) of 1 mM5-HT.
Samples were collected after 7 days agitation at 37 °C, 1200 rpm. Scale bars correspond to
200 nm.
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Fig. 4. CD spectra of 10 μM unagitated AS (dashed line); AS ﬁbrils (solid line) and AS:5-
HT=1:10 (dash-dotted line; corrected with respect to the residual monomeric
component) after 100 h agitation at 37 °C, 1200 rpm.
556 S.F. Falsone et al. / Biochimica et Biophysica Acta 1814 (2011) 553–561ﬁlter device (Millipore, Billerica, MA) with a membrane cutoff of
3 kDa. The amount of 5-HT recovered in the ﬂow-through was
detected by ﬂuorescence emission spectroscopy after excitation of
295 nm. Emission spectra were recorded between 300 and 400 nm on
a Cary Eclipse ﬂuorescence spectrometer.
2.8. Denaturing SDS–PAGE
A 100 μM AS solution in 20 mM Tris–HCl, 150 mM NaCl, 3 mM
NaN3, pH 7.4, was agitated at 37 °C and 1200 rpm in the absence and
presence of 1 mM 5-HT. Two microliter aliquots were collected at
given times and resolved on a 4%–12% SDS–PAGE gel. Proteins were
visualized by silver staining.
3. Results
3.1. 5-HT promotes the accumulation of partially structured aggregates
We ﬁrst tested whether 5-HT was able to inﬂuence the growth of
AS amyloid ﬁbrils by agitating an AS sample at 37 °C over several days.
Fibril growth was monitored by the dye Thioﬂavin T (ThioT), which
exhibits a ﬂuorescence emission maximum at 482 nmwhen bound to
mature ﬁbrils but not to monomeric or pre-ﬁbrillar species [40]. ThioT
ﬂuorescence increased in the absence of 5-HT indicated that ﬁbril
growth proceeded following an initial lag phase, reaching a plateau
around 80 h (Fig. 1A). ThioT ﬂuorescence was suppressed when a 10-
fold excess of 5-HT was present (Fig. 1A). The addition of different
amounts of 5-HT to an agitating AS solution (Fig. 1B) showed that 5-
HT was able to abolish the assembly of AS into mature amyloid ﬁbrils
in a concentration dependent way, even at sub-stoichiometric levels.
Unless explicitly stated, the following experiments were all per-
formed at a 10-fold 5-HT excess to ensure complete AS saturation.
In parallel to ThioT ﬂuorescence, the turbidity of the sample
solutions was measured, which deﬁnes the formation of light
scattering particles. The turbidity of the AS solution in the absence
of 5-HT (Fig. 2A) increased already during the ThioT lag-phase
(Fig. 1A). This is in accordance to previous studies [41,42], which
describe the build-up of pre-amyloid, ThioT-negative aggregates
preceding ﬁbril assembly. A less prominent increase in turbidity was
observed in the presence of 5-HT, suggesting the accumulation of
non-amyloidogenic aggregates.
We employed dynamic light scattering (DLS) for a more detailed
analysis of the size composition of these aggregates. Fig. 2B shows the
Stokes radii of the most prominent AS aggregates appearing in
solution over time in the absence or in the presence of 5-HT.
Monomeric AS had a Stokes radius of 2.6 nm, consistent with previous
reports [43]. We also observed for AS alone that higher order species
with mean radii up to 1 μmwere generated over time, corresponding
to the assembly of amyloid ﬁbrils. The addition of 5-HT prevented the
maturation of these amyloid ﬁbrils in favor of aggregates with an
initial mean size of up to 10 nm, which increased to approximatively
150 nm within 3–4 days (Fig. 2B). As shown by SDS–PAGE analysis,
these aggregates were composed of differently sized SDS-resistant
oligomers (Fig. 2C). Ultracentrifugation analysis indicated that the
aggregates partitioned in the soluble fraction (Fig. S1). Therefore, 5-
HT does not suppress the assembly of AS completely but rather
promotes the accumulation of soluble intermediate aggregates
instead of mature amyloid ﬁbrils, as suggested for other ligands
[17,19,23,44].
Fig. 2C also shows a time-dependent shift of monomeric AS to a
slightly higher sized band. We speculate that this might derive from a
covalent reaction between AS and an oxidized derivative of 5-HT. In
support to this, we noticed that this band shift was not observed
under reducing conditions (Fig. 2D), suggesting that a covalent 5-HT:
AS adduct might indeed form during the reaction. However, this
adduct would not account for ﬁbril suppression as 5-HT was still ableto suppress amyloid growth in the presence of the reducing agent
thiosulfate (Fig. 2E) [45]. Also, SDS-resistant dimer and tetramer
bands appeared even under reducing conditions (Fig. 2D). These
results both indicate that 5-HT was able to efﬁciently suppress ﬁbril
formation independently of an oxidative adduct accumulating during
the reaction.
To visualize the morphology of the observed aggregates, we
recorded TEM images of samples collected at the end of the amyloid
growth curve. In the absence of 5-HT, the sample was composed
predominantly of entangled ﬁbrils of varying length and approximate
5 nm width, along with a minor amount of smaller globular
aggregates (Fig. 3A). In the presence of 5-HT, heterogeneously sized,
small spherical (b50 nm) and large granular (100–200 nm) aggre-
gates were the predominant species (Fig. 3B).
In order to structurally characterize these aggregates, we used far-
UV circular dichroism spectroscopy which proved very useful to
distinguish the secondary structure conformation of differently folded
AS species [46]. The spectrum of monomeric AS featured intrinsically
unstructured patterns, i.e., a minimal signal readout, followed by a
strong negative signal minimum below 210 nm (Fig. 4, dashed line).
In contrast, the CD spectrum of mature AS amyloid ﬁbrils was typical
of β-sheets (Fig. 4, solid line), which corresponds to the conformation
that AS adopts in amyloid ﬁbers [7]. The signal showed a negative
minimum around 220 nm and a positive ellipticity below 210 nm. For
5-HT generated AS aggregates, we observed a prominent CD-signal
increase below 210 nm and a slight decrease of the CD-signal around
220 nm, compared to monomeric AS (Fig. 4, dash-dotted line). This
corresponded to a decrease of the unstructured signal component
in favor of the structured component, accounting for a reduced
Table 1
Secondary structure deconvolution analysis of the CD spectra as shown in Fig. 4.
α-Helix β-Sheet Unstructured
Monomeric AS 6.8% 2.1% 91.9%
5-HT-induced aggregates 10.3% 32.2% 56.8%
Amyloid ﬁbers 5.8% 59.8% 34.2%
557S.F. Falsone et al. / Biochimica et Biophysica Acta 1814 (2011) 553–561conformational ﬂexibility of AS within these aggregates. As shown
by secondary structure deconvolution of the respective CD spectra
(Table 1), structural disorder decreased from 91.9% for monomeric ASFig. 6. Overlay of one-dimensional
1
H spectra of 10 μM 5-HT agitated with 100 μM AS at 37 °
and an aromatic side chain signal of AS (right) were taken as representative signals.
Fig. 5. (A) ThioT amyloid growth kinetics of 100 μM AS (■), AS:5-HT=1:10, with 5-HT
added at mid-amyloid growth (arrow) (○). (B) TEM images of 100 μM AS at mid-
amyloid growth in the absence of 5-HT and (C) after 100 h in the presence of 1 mM 5-
HT added at mid-amyloid growth. Scale bars correspond to 200 nm.to 56.8% for intermediate aggregates. This was paralleled by a gradual
increase of the beta-sheet component from 2.1% for monomeric AS to
34.9% for the intermediate aggregates and ﬁnally to 59.8% for the
amyloid ﬁber sample. This indicates that the aggregates observed in
the presence of 5-HT are partially structured and display a signiﬁcant
beta-sheet structural content.
We noticed that, in aging aggregate preparations stored at RT
containing AS and 5-HT, short amyloid ﬁbrils were slowly formed
after 6–8 weeks (Fig. S2(A)). We thus assumed that the observed
aggregates might represent kinetically stabilized “on-pathway”
components of amyloid assembly. To discriminate between “on-
pathway” and “dead-end,” we examined if they could act as
nucleation seeds to promote AS amyloidogenesis. Nucleation consists
of the early formation of transient, pre-ﬁbrillar intermediates, which
then convert into amyloids [6]. For this purpose, we induced ﬁbril
growth in the absence and in the presence of 5-HT-generated
aggregates. Fig. 1A and Fig. S2(B) show that amyloidogenesis was
accelerated when these aggregates were used for seeding, identifying
them as “on-pathway.”
3.2. 5-HT binds to intermediate aggregates
We observed that sub-stoichiometric amounts of 5-HT were
sufﬁcient to affect AS amyloidogenesis (Fig. 1B and Fig. S2(C)). Also,
ﬁbril growth was interrupted by the addition of 5-HT during the
amyloid mid-growth phase (Fig. 5). This led us to suppose that, rather
than binding to monomeric AS, this neurotransmitter binds to and
stabilizes intermediate AS aggregates once they have formed.
To prove our hypothesis, we used two-dimensional heteronuclear
correlation NMR spectroscopy, which is suitable for measuring
binding of a given ligand to a protein. The
1
H-
15
N HSQC spectrum of
monomeric AS recorded at 25 °C showed limited signal dispersion
typical for intrinsically unstructured proteins (Fig. S3). For 5-HT
binding to monomeric
15
N-AS, we expected signiﬁcant shifts or
intensity changes for some of the signals, as previously observed for
other AS ligands [16,17,47,48]. However, this did not occur upon the
addition of 5-HT, as the spectra are virtually unchanged. This argues
against binding of 5-HT to AS monomers.
We expected that the
1
H-resonance signals of 5-HT should be
sensitive to an interaction with AS aggregates. To show this, we
recorded
1
H-NMR spectra of an agitating 5-HT:AS mixture and
monitored signal variations over time. The signals of both 5-HT
(Fig. 6, left) and AS (Fig. 6, right) displayed decreasing intensity
within the ﬁrst 4 days of agitation. The decrease in AS signal
intensities was indicative of aggregate formation. As these are well
beyond the NMR size limit, they yield extremely broad andC. The well separated signal of the 1-CH2 group of the 2-aminoethyl chain of 5-HT (left)
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558 S.F. Falsone et al. / Biochimica et Biophysica Acta 1814 (2011) 553–561undetectable signals. Their formation can thus be seen indirectly in
the NMR spectra by the decrease of signal intensities. For 5-HT, a
signiﬁcant reduction of resonance intensities was observable only
after 48 h, which can be explained by binding of 5-HT to accumulating
aggregates rather than to monomers. A signal decrease was not
observed for 5-HT in the absence of AS (Fig. S4). Since there were no
detectable chemical shift changes of 5-HT and we did not ﬁnd a
saturation transfer difference (STD) effect on 5-HT (see supplemen-
tary data, Fig. S5), the binding of 5-HT to AS aggregates has to be
relatively tight (KdbmM). By ﬁnding the same results under reducing
conditions, we could exclude that a covalent interaction between
AS and an oxidized derivative of 5-HT might prevent STD (see
supplementary data, Fig. S5).
An analogous result was observed by ultraﬁltration analysis
(Fig. 7). AS was agitated in the presence of 5-HT, and aliquots
collected at different times of amyloidogenesis were centrifuged
through an ultraﬁltration device with a membrane cutoff of 3 kDa,
which is permeable for unbound 5-HT but not for 5-HT bound to AS.
As a consequence, binding of 5-HT to AS was expected to reduce the
recovery of free 5-HT in the ﬂow-through. The assay shows that
monomeric AS (t=30 min) was not able to retain 5-HT, which was
recovered in the ﬁltrate. In contrast, the recovery of 5-HT was
signiﬁcantly lower (74% less) for a sample collected at t=100 h,
indicating that a considerable amount of 5-HT remained bound to
forming aggregates. These results show that 5-HT binds to AS
aggregates rather than to monomeric AS.0 20 40 60 80 100 120
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C3.3. The interaction between 5-HT and AS is charge sensitive
The above results indicate that the 5-HT binding regions might
become exposed during amyloidogenesis. The acidic C-terminal
region of AS becomes more accessible after the release of long-
range contacts with the NAC core domain [49,50] and ligands such as
catechols, polyamines, and some cations target this region [48,51–53].
To test if 5-HT binds to the C-terminal region, we tested an AS
truncation mutant (ASΔ96) lacking the whole C-terminal region (aa
97–140). Fig. 8A shows the amyloid growth curve of ASΔ96, in the
absence and in the presence of 5-HT. In direct contrast to what we
observed for full-length AS (Fig. 1), 5-HT had a minimal effect on
ASΔ96 amyloid growth (see also Fig. S2(D) and Fig. S2(E)). This0 20 40 60 80 100 120
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Fig. 8. ThioT amyloid growth kinetics of (A) 150 μM ASΔ96 in the absence (■) and in
the presence of 1 mM 5-HT (□); (B) 100 μM AS in the absence (■) and in the presence
of 1 mM 5-HT (□) with 300 mM NaCl; (C) 100 μM AS in the absence (■) and in the
presence of 1 mM 5-HT (□) at pH 11.6; (D) 100 μM AS in the absence (■) and in the
presence of 1 mM 5,7-HT (▼) or 1 mM 5-HIAA (○).
320 340 360 380
0
50
100
150
200
250
300
Fl
uo
re
sc
en
ce
 e
m
is
si
on
 
ar
bi
tra
ry
 c
ou
nt
s 
Wavelength (nm)
Fig. 7. Fluorescence emission spectra of 5-HT recovered in the ﬂow through after
ultraﬁltration through a 3 kDa cutoff membrane: 5-HT in the absence of AS after 0 h
(black solid line) and after 100 h agitation at 37 °C, 1200 rpm (dark gray solid line).
5-HT in the presence of AS after agitation at 37 °C, 1200 rpm for 30 min (dashed
line), 24 h (dotted line), 48 h (dash-dotted line), and 100 h (short dotted line).
Fig. 9. Molecular formulae of the three compounds used in this study.
559S.F. Falsone et al. / Biochimica et Biophysica Acta 1814 (2011) 553–561suggests that the C-terminal region of AS is required for the efﬁcient
suppression of 5-HT mediated amyloid growth.
As the C-terminal region of AS has a negative net charge and 5-HT
is cationic at physiological pH [54], electrostatic forces might drive the
interaction. This was indeed the case since 5-HT was no longer able to
inhibit amyloidogenesis when the ionic strength of the solution was
increased (300 mM NaCl) (Fig. 8B, Fig. S2(F), Fig. S2(G)). A similar
effect was observed after neutralizing the positive charge of the
aliphatic 5-HT amino group by increasing the pH of the buffer above
its pKa-value of 9.97 (Fig. 8C, Fig. S2(H), Fig. S2(I)) [54]. 5-HT scaffold
modiﬁcations provided further indications for charge effects. 5,7-
hydroxytryptamine (5,7-HT), which differs from 5-HT by an addi-
tional hydroxy group at the aromatic ring (Fig. 9), was also able to
suppress amyloid assembly (Fig. 8D and Fig. S2(J)). In contrast, 5-
hydroxyindoleacetic acid (5-HIAA), a 5-HT metabolite where the
positively charged aliphatic amino group of 5-HT is replaced by a
negatively charged carboxy group (Fig. 9), did not suppress amyloid
growth (Fig. 8D and Fig. S2(K)). In contrast, dopamine mediated
inhibition of AS ﬁbrillization is not signiﬁcantly modulated by
electrostatic forces since high salt conditions (500 mM NaCl) had no
effect [26]. Collectively, these results demonstrate that charge
perturbations critically affect the ability of 5-HT to efﬁciently interfere
with AS amyloidogenesis.4. Discussion
The intrinsic structural disorder of the PD key protein AS accounts
for ligand binding promiscuity and conformational variance. BothFig. 10. An in vitro model for the 5-HT-modulated suppression of AS amyloidogenesis. In a
the consequent build-up of intermediate aggregates (B), the C-terminal region of AS (da
the C-terminal region (C) and arrest the build-up of mature amyloid ﬁbrils (F). Instea
conversion into amyloid ﬁbrils is kinetically disfavored (E).issues are coupled to the generation of pathogenic AS aggregates. Yet,
the exact circumstances dictating the formation of these species are
unclear.We demonstrated that the neurotransmitter 5-HT profoundly
inﬂuenced amyloidogenesis of AS, which was altered in favor of “on-
pathway” intermediates.
We show that 5-HT targets the C-terminal region of AS, as reported
for dopamine and other functionally unrelated ligands [48,51–53].
In contrast to them, 5-HT does not bind directly to monomeric AS
molecules. Consequently, 5-HT does not inﬂuence initial steps of
amyloidogenesis. Rather, 5-HT intervenes in the AS ﬁbril assembly at a
given intermediate growth stage, when partially folded soluble
aggregates have already accumulated. This interrupts their further
maturation. Reinke et al. [32] proposed a similar mechanism for a set
of indolic derivatives which bind preferentially to pre-amyloid
intermediates of the Alzheimer disease peptide Aβ. This suggests
common interaction properties between indoles and different
amyloid-forming proteins. The link between 5-HT and the non-
motor symptoms of PD [33,35] might account for a pathophysiological
relationship between this particular neurotransmitter and AS in PD.
Based on our results, we outline a model for the 5-HT-mediated AS
aggregation (Fig. 10). The initial phase involves the 5-HT-independent
interaction of AS monomers to form the early small intermediates
(Fig. 10A). This might be initiated by the loosening of intramolecular
constraints between the C-terminal region and the hydrophobic core
region, as proposed by Dedmon et al. [49,50]. The C-terminal region is
not assembled within the β-sheet scaffold which is generated during
ﬁber elongation but remains rather unstructured and solvent exposed
(Fig. 10B) [55,56]. We suggest that this facilitates the consequent
interaction with 5-HT (gray spheres) (Fig. 10C), which takes place
during the pre-ﬁbrillar phase. Since the C-terminal region of AS is
critical for the further maturation of pre-ﬁbrils into amyloid ﬁbers
[55], it is likely that binding of 5-HT to this region interferes with the
assembly of mature ﬁbrils (Fig. 10F). As a result, ﬁbril generation is
inhibited (Fig. 10E), resulting in the accumulation of the partially
structured and kinetically stabilized intermediate aggregates (Fig.
10D).
It remains to be established whether the 5-HT/AS interaction is
either pathological or physiologically relevant in vivo. Despite the
promotion of “on pathway” aggregation by 5-HT, the occurrence of
SDS-resistant oligomeric intermediates (Fig. 2C) similar to those
observed for dopamine induced “off-pathway” aggregation [17,26]
suggests some mechanistic overlap between these two processes. We
speculate that an interaction between 5-HT and AS in serotonergic
neurons might trigger neurotoxic effects paralleling those suggested
for dopamine and AS in dopaminergic neurons. This is supported by
the occurrence of AS-positive Lewy inclusions in serotonergic neurons
[57], which might imply molecular events similar to those eventually
leading to dopaminergic cell death.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbapap.2011.02.008.ﬁrst step, amyloid-promoting conformational rearrangements of AS occur (A). During
shed line) remains solvent exposed [55,56]. 5-HT molecules (gray spheres) bind to
d, intermediate, partially structured, toxic aggregates become stabilized (D). Their
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